Physician profile
Christopher Song
NPI 1477059111
$1,440.01
in general payments reported to CMS, 2019-2025
23 companies · $806 in 2025
The $806 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.05 · 2023: $33.40 · 2024: $579 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,418.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $269.71 | 2024-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $153.72 | 2024-2025 | |
| Irhythm Technologies, INC. | $151.00 | 2024 | Zio Xt Patch, Zio Monitor |
| Baxter Healthcare | $138.73 | 2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Cvrx, INC. | $133.87 | 2024-2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $85.83 | 2024-2025 | Onpattro |
| Novo Nordisk INC | $75.28 | 2024-2025 | Wegovy |
| Amgen INC. | $68.74 | 2024 | Repatha |
| Merck Sharp & Dohme LLC | $52.30 | 2024-2025 | Verquvo |
| Philips North America LLC | $44.71 | 2022-2024 | (5044) Mcot |
| Kiniksa Pharmaceuticals, LTD. | $33.40 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $30.77 | 2024 | Nexletol |
| Kestra Medical Technology Services, INC. | $27.82 | 2025 | Assure Wcd |
| Heartflow, INC. | $21.97 | 2025 | |
| Scpharmaceuticals INC. | $19.69 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.08 | 2025 | Jardiance |
| Watermark Medical, INC. | $18.91 | 2024 | |
| Pfizer INC. | $17.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $16.68 | 2025 | Eliquis |
| Ionis Pharmaceuticals, INC. | $16.38 | 2025 | Tryngolza |
| Glaxosmithkline, LLC. | $15.45 | 2025 | Shingrix, Arexvy |
| Azurity Pharmaceuticals, INC. | $14.78 | 2024 | Edarbyclor |
| Astrazeneca Pharmaceuticals LP | $14.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.